Protagenic Therapeutics, Inc.
PTIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$25 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $0 | $13 | $13 | $25 |
| Gross Profit | $0 | -$13 | -$13 | -$50 |
| % Margin | – | – | – | 200% |
| R&D Expenses | $273 | $394 | $880 | $903 |
| G&A Expenses | $160 | $814 | $568 | $740 |
| SG&A Expenses | $160 | $814 | $568 | $740 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $681 | $1,123 | -$0 | -$0 |
| Operating Expenses | $1,114 | $2,332 | $1,448 | $1,643 |
| Operating Income | -$1,114 | -$2,344 | -$1,448 | -$1,643 |
| % Margin | – | – | – | 6,534.6% |
| Other Income/Exp. Net | $244 | -$2,713 | $8 | $89 |
| Pre-Tax Income | -$869 | -$5,058 | -$1,440 | -$1,554 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$869 | -$5,058 | -$1,440 | -$1,554 |
| % Margin | – | – | – | 6,180.6% |
| EPS | -0.47 | -1.37 | -2.75 | -0.24 |
| % Growth | 65.7% | 50.2% | -1,045.8% | – |
| EPS Diluted | -0.47 | -1.37 | -2.75 | -0.24 |
| Weighted Avg Shares Out | 1,849 | 3,701 | 523 | 6,500 |
| Weighted Avg Shares Out Dil | 1,849 | 3,701 | 523 | 6,500 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $8 | $9 |
| Interest Expense | $34 | $239 | $0 | $0 |
| Depreciation & Amortization | $0 | $13 | $13 | $13 |
| EBITDA | -$1,114 | -$4,806 | -$1,436 | -$1,541 |
| % Margin | – | – | – | 6,128.9% |